9.11.2021 08:15:00 CET | Monsenso |
Investor Nyheder
Monsenso har underskrevet en aftale med Awakn Life Sciences, en global biotekvirksomhed, om at understøtte virksomhedens medicinske psykedeliske behandlinger.
Awakn Life Sciences er en global biotekvirksomhed, førende indenfor psykedelisk medicin til behandling af misbrug og afhængighed. I oktober 2021 påbegyndte implementeringen af Monsenso’s digitale sundhedsløsning i Awakn Life Sciences kliniske praksis som et værktøj til at understøtte patienter i deres behandling, samt til opsamling af real-world patientindsigter og til at guide klinisk beslutningstagning og personliggøre behandlingen.
Psykisk sygdom og afhængighed er nogle af de største udfordringer for folkesundheden i verden.
Næsten en milliard mennesker verden over lider af psykisk sygdom, for hvem der er for få effektive behandlinger til ud over mestringsstrategier og symptombehandling. Med globale udgifter til mental sundhed anslået til at nå 16 billioner USD i 2030 (målt ved tabt økonomisk produktion)[1], er det afgørende at der udvikles effektive nye behandlinger for at afhjælpe de nuværende mangler.
Psykedelisk assisteret terapi anses i dag som værende en potentiel løsning på dette behandlingsvakuum. I begyndelsen af det 20. århundrede var disse stoffer stærkt regulerede og havde en negativ konnotation. I dag har en stigende mængde evidens og det presserende udækkede behov hos patienterne imidlertid fået klinikere og sundhedsmyndigheder til at overveje dem som en mulig behandlingsmulighed.
Psykedelisk assisteret psykoterapi repræsenterer et paradigmeskifte inden for psykiatrisk behandling
Psykedeliske rusmidler er stoffer, der ændrer opfattelse og humør og påvirker forskellige kognitive processer. Når de bruges i forbindelse med psykoterapi, kan de sætte patienter i en midlertidig tilstand, hvor patienterne bedre kan bearbejde minder, følelser og tidligere traumer[2], hvilket gør det muligt for dem at give slip på ting, der tidligere har gjort dem urolige[3] . Af samme årsag har psykedelisk assisteret psykoterapi vist sig effektiv til behandling af lidelser, der historisk har været svære at behandle[4] og betragtes i dag som et lovende vendepunkt inden for psykiatrisk behandling[5,6,7].
Til trods for at psykedeliske rusmidler har ansporet stor interesse i life science-industrien, er det kun få psykedeliske selskaber, der i øjeblikket behandler patienter i kliniske rammer. Awakn Life Sciences lancerede Storbritanniens første psykedelisk assisterede klinik i Bristol, efterfulgt af klinikker i London og Manchester, der tilbyder evidensbaserede psykedeliske terapier til behandling af afhængighed og andre mentale lidelser, og har nu også åbnet en klinik i Oslo, Norge med planer om at skalere hurtigt over hele Europa.
I oktober 2021, påbegyndte Awakn Life Science implementeringen af Monsenso’s digitale sundhedsløsning i klinisk praksis til at støtte patienter gennem deres behandlingsforløb og til at opsamle patientdata til at understøtte kliniske beslutninger og til at personliggøre behandlingen.
“Vi er glade for at arbejde sammen med Awakn Life Science om at understøtte nye behandlingsmuligheder for mennesker, der har oplevet utilstrækkelige behandlingsresultater. Vi ser frem til at samarbejde med Awakn Life Sciences og være en del af deres vækstrejse,” siger administrerende direktør for Monsenso, Thomas Lethenborg.
Awakns administrerende direktør, Anthony Tennyson, tilføjer: “Der er et meget kritisk behov for at levere løsninger og håb til mennesker, der lider af psykiske sygdomme og afhængighed. Vi er glade for at samarbejde med Monsenso for bedre at kunne interagere med klienter under hele deres behandling, få indsigt til at understøtte kliniske beslutninger og forbedre sundhedsresultater, samt generere patientindsigt til at understøtter vores forsknings- og behandlingsudviklingsprogrammer.”
Om Awakn Life Science
Awakn Life Sciences er en børsnoteret (NEO: AWKN) (OTCQB: AWKNF) bioteknologivirksomhed med klinisk drift; som forsker, udvikler og leverer psykedelisk medicin for at behandle afhængighed bedre. Awakns team består af verdensførende kemikere, videnskabsmænd, psykiatere og psykologer, som udvikler og fremmer den næste generation af psykedeliske stoffer, terapier og muliggørende teknologier til at behandle afhængighed.
[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/
[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508
[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.
[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508
[6]https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-for-psychiatric-disorders/
[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning for mentale lidelser. Vores mission er at bidrage til bedre mental sundhed til flere personer og lavere omkostninger. Vores løsning bidrager til optimering af behandlingen af psykiske lidelser og giver et detaljeret overblik over patienters mentale sundhed via indsamling af data om mental tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig opsporing og intervention. Baseret på vedvarende forskning og udvikling er vores team opsat på at udvikle løsninger, der passer ind i brugernes liv, øger patienters livskvalitet og forbedrer effekten af behandlingen. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
9.11.2021 08:15:00 CET | Monsenso |
Investor News
Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company, to support the company’s medical psychedelic treatments.
Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.
Mental illness and addiction are some of the biggest public health challenges facing the global community.
Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps.
Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.
Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment
Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].
While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.
In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.
“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.
Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.
About Awakn Life Science
Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world-leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.
[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/
[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508
[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.
[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508
[6]https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-for-psychiatric-disorders/
[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
About Monsenso
Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
